Dermata Expands Patent Portfolio with Issuance of Patent for DMT410
Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program
Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds
Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package